PAH ther­a­py tanks in Phase III, oblit­er­at­ing Bellerophon's stock

Bellerophon, a small com­pa­ny in New Jer­sey, has lost its bet that it could treat high blood pres­sure in the lungs with its last-stage lead ther­a­py. The com­pa­ny’s stock is crash­ing on the news that its Phase III tri­al is be­ing scrapped mid­way.

Why is Bellerophon ditch­ing the ef­fort? Fu­til­i­ty. An in­ter­im analy­sis showed the first 75 pa­tients en­rolled in the pul­monary ar­te­r­i­al hy­per­ten­sion (PAH) tri­al were not re­spond­ing as hoped. The Da­ta Mon­i­tor­ing Com­mit­tee deemed the over­all change in 6 minute walk dis­tance — the pri­ma­ry end­point of the tri­al — “in­suf­fi­cient to sup­port the con­tin­u­a­tion of the study.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER